BRAFV600E基因突变的结直肠癌是属于难治性肠癌，约占结直肠癌总数的5%~21%，是以侵袭性高、治疗效果不佳和预后差为特征 ...

The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.

Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom. *Corresponding Author: Michael J. Dubec, Christie Medical Physics and Engineering, The Christie ...

在临床试验中（PHAROS研究），专家们对59名新诊断的患者进行了观察，其中不仅有15%的患者实现了完全缓解（CR），同时还有59%的患者达到了部分缓解（PR）。而为了更好地了解这种疗法的长期效果，研究者们进一步随访得知，64%的患者至少维持了12个月的缓解，令人刮目相看。但值得注意的是，治疗过程中的不良反应同样不容忽视，恶心、腹泻与疲劳等副作用常常出现。

This pathway mediates the regulation of cell proliferation, differentiation, and survival in response to extracellular signals. The BRAFV600E mutation simulates phosphorylation in the activating ...

Pierre Fabre Laboratories has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adults with advanced ...

Assistant Secretary Ariel Valencia, DoH Calabarzon Center for Health Development regional director, says a 12-year-old mpox patient from Balayan, Batangas is recovering from the illness. Valencia was ...

Exceptional Response of BRAFV600E-Mutated Acinar Cell CUP to BRAF/MEK Inhibition The following represents disclosure information provided by authors of this manuscript. All relationships are ...

This is generally a well-designed and carefully conducted study that is likely to be of interest to many both inside and outside of the field of lung tumorigenesis and normal lung development and ...